1. Introduction {#sec0005}
===============

Glioblastoma multiforme is the most common and most aggressive type of primary brain tumors. Despite improved surgical techniques, therapies and radiotherapies, prognosis for this type of pathology remains very poor: most patients die within 12--18 months from diagnosis [@bib0005].

There is however a small percentage of Patients affected by glioblastoma multiforme who survive 3 years or longer [@bib0010], [@bib0015]. Finally there are some exceptional cases, such as the one we are describing in this article, when people have survived decades after surgical removal of a glioblastoma without any recurrence.

This work has been reported in line with the SCARE criteria [@bib0020].

2. Presentation of case {#sec0010}
=======================

In 1994, a 44 year-old man was admitted to the Neurosurgical department of the Military Hospital of Rome; for about a month he had been suffering from intense headache and loss of strength of the left arm. An MRI scan showed the presence of a tumor in the posterior part of the right frontal lobe ([Fig. 1](#fig0005){ref-type="fig"}).

The Patient underwent surgery: the tumor was intraparenchymal and looked like a glioma. It was removed seemingly in-toto. Histological examination showed the neoplasia to be a glioblastoma multiforme.

The patient's postoperative course was uneventful and the loss of strength in the left arm disappeared within three weeks.

After the operation the patient underwent whole-brain radiotherapy (total dose 55 Gy) and nitrosurea-based chemotherapy.

Three months after surgery the patient had a first check up CT scan to see if there was any recurrence of the tumor. Since then, he has had regular scans, further and further apart in time, which to-date have shown no presence of the pathology. [Fig. 2](#fig0010){ref-type="fig"} shows the last MRI scan carried out in July 2016, 22 years after the operation. The neurological conditions of the patient, who is currently 66, are normal.

In the Anatomic Pathology Archive of our hospital we kept the microscope slides with the cell samples of this case. Before writing this article we have showed the slides to three neuropathologists who have all confirmed that the morphological appearance of the histological samples is that typical of a glioblastoma, thus confirming the original histological report ([Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"})

3. Discussion {#sec0015}
=============

In the last ten years neuronavigation techniques associated also with functional NMR [@bib0025], as well as the use of substances like 5-Aminolevulinic acid hydrochloride [@bib0030], which mark and thus make tumoral tissue easier to identify during an operation, have improved surgery for cerebral gliomas; in fact they allow for a more thorough excision and they also lower the risk of causing functional damage during surgery.

Therapy for gliomas has also evolved, as indicated by the introduction of monoclonal chemotherapy [@bib0035] and telozolomide treatment combined with radiotherapy [@bib0040].

Together with the traditional fractionated external beam RT (EBRT), nowadays there are new radiotherapy techniques like the intensity-modulated RT (IMRT) and stereotactic radiosurgery [@bib0045].

Despite the advancements, median survival, especially for Grade 4 gliomas and for glioblastomas doesn't exceed 12--18 months from diagnosis [@bib0050]. A very small percentage of cases showed \>3 years survival, in other words long-survival. There have been exceptional cases [@bib0055], [@bib0060] of long-survival spanning 10 years or more, without tumor recurrence, so as to deem those affected 'cured'. The possibility of a complete recovery from glioblastoma was suggested by the Yamada et al. case [@bib0065]: after dying of skull trauma, an autopsy limited to the brain was performed on a patient who had undergone surgery for a glioblastoma multiforme 6.5 years before; the team carefully searched for the presence of cancer without success, despite collecting numerous histological samples. There was simply no trace of the tumor. Cases like ours, with more than 20 years survival span and no recurrence are extremely rare [@bib0070], [@bib0075], [@bib0080], [@bib0085] ([Table 1](#tbl0005){ref-type="table"}).

In the Literature [@bib0005], [@bib0010] it has been noted that long-survival for glioblastoma multiforme is linked to age, with better rates for those below 65 years of age, but also to aggressive and complete surgical excision, a good Karnofsky index score before surgery and the application of radiotherapy after surgery.

Some authors remarked that the occurrence of a bacterial infection in the location of the operation after the removal of a glioma can improve a patient's longevity, probably due to a stronger immune response from the body [@bib0090], [@bib0095]. Other authors have linked long-survival after surgery to the molecular make-up of a specific glioma, for example the abscence of *epidermal growth factor receptor* gene amplification, the presence of MGMT promotor hypermethylation, IDH1 mutation [@bib0100]. There is so far no satisfactory explanation as to why certain cases can be deemed cured, but total -- gross resection of the tumor followed by radiotherapy and a Patient's individual immune response certainly play an important role.

4. Conclusion {#sec0020}
=============

Despite research and improved therapies, today a glioblastoma diagnosis equates to a death sentence. However the fact that there are extremely rare cases of long-term survival and even zero recurrence of the pathology should serve as a stimulus to continue the research effort and not give up the fight against this tumor on a day-to-day basis.
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![The MRI scan shows the presence of a tumor in the posterior part of the right frontal lobe. The tumor absorbs the contrast medium, in its interior it can be seen an area of necrosis,and it is surrounded by cerebral edema.](gr1){#fig0005}

![The MRI scan showed no presence of the pathology.](gr2){#fig0010}

![(10x) Hematoxilin and Eosin, demonstrating an hypercellular cluster of the glioma with microcystic degeneration, bizarre pleomorphic cells; high grade nuclear atypia with prominent nucleoli.](gr3){#fig0015}

![(10x) The lesion shows (A) a strong GFAP immunoreactivity and 3--(B) high proliferating index (Ki67 immunostaining).](gr4){#fig0020}

###### 

20-plus-year survival cases.

Table 1

  Authors           Age and Sex   Survival Time and Status
  ----------------- ------------- --------------------------
  ELVIDGE, BARONE   30 yrs, W     22 yrs alive
  JOHNSON et al     32 yrs, M     22 yrs alive
  BUCY et al        30 yrs, M     25 yrs alive
  SALFORD et al     8 yrs, M      23 yrs alive
  CARUSO et al      44 yrs, M     22 yrs alive

M = man, W = woman, yrs = years
